Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Oncogene-induced senescence and tumour control in complex biological systems.

Galluzzi L, Vitale I.

Cell Death Differ. 2018 Apr 17. doi: 10.1038/s41418-018-0102-y. [Epub ahead of print] No abstract available.

PMID:
29666473
2.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

3.

Everybody In! No Bouncers at Tumor Gates.

Vitale I, Galluzzi L.

Trends Genet. 2017 Dec 22. pii: S0168-9525(17)30226-3. doi: 10.1016/j.tig.2017.12.006. [Epub ahead of print]

PMID:
29277455
4.

Replication stress in colorectal cancer stem cells.

Manic G, De Maria R, Vitale I.

Oncotarget. 2017 May 20;8(53):90606-90607. doi: 10.18632/oncotarget.18045. eCollection 2017 Oct 31. No abstract available.

5.

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.

Di Benedetto A, Ercolani C, Mottolese M, Sperati F, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Humphries MP, Di Lauro L, Barba M, Vitale I, Ciliberto G, Speirs V, De Maria R, Maugeri-Saccà M.

Sci Rep. 2017 Aug 14;7(1):8078. doi: 10.1038/s41598-017-07366-7.

6.

Calcium signaling and cell cycle: Progression or death.

Humeau J, Bravo-San Pedro JM, Vitale I, Nuñez L, Villalobos C, Kroemer G, Senovilla L.

Cell Calcium. 2018 Mar;70:3-15. doi: 10.1016/j.ceca.2017.07.006. Epub 2017 Jul 25. Review.

PMID:
28801101
7.

Driving to Cancer on a Four-Lane Expressway.

Galluzzi L, Vitale I.

Trends Genet. 2017 Aug;33(8):491-492. doi: 10.1016/j.tig.2017.06.003. Epub 2017 Jun 28.

PMID:
28668385
8.

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Musella M, Manic G, De Maria R, Vitale I, Sistigu A.

Oncoimmunology. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424. eCollection 2017. Review.

9.

Caspase 2 in mitotic catastrophe: The terminator of aneuploid and tetraploid cells.

Vitale I, Manic G, Castedo M, Kroemer G.

Mol Cell Oncol. 2017 Mar 10;4(3):e1299274. doi: 10.1080/23723556.2017.1299274. eCollection 2017.

10.

DNA Damage in Stem Cells.

Vitale I, Manic G, De Maria R, Kroemer G, Galluzzi L.

Mol Cell. 2017 May 4;66(3):306-319. doi: 10.1016/j.molcel.2017.04.006. Review.

11.

ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy.

Antonelli M, Strappazzon F, Arisi I, Brandi R, D'Onofrio M, Sambucci M, Manic G, Vitale I, Barilà D, Stagni V.

Oncotarget. 2017 Mar 28;8(13):21692-21709. doi: 10.18632/oncotarget.15537.

12.

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Pallocca M, Amoreo CA, Sperati F, Di Franco S, Barresi S, Policicchio E, De Luca G, De Nicola F, Mottolese M, Zeuner A, Fanciulli M, Stassi G, Maugeri-Saccà M, Baiocchi M, Tartaglia M, Vitale I, De Maria R.

Gut. 2018 May;67(5):903-917. doi: 10.1136/gutjnl-2016-312623. Epub 2017 Apr 7.

13.

Spontaneous DNA damage propels tumorigenicity.

Vitale I, Kroemer G.

Cell Res. 2017 Jun;27(6):720-721. doi: 10.1038/cr.2017.43. Epub 2017 Mar 31.

PMID:
28361897
14.

DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.

Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P, Sergi D, Di Lauro L, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vitale I, Barba M, Buglioni S, Mottolese M, Fanciulli M, De Maria R, Maugeri-Saccà M.

Int J Cancer. 2017 Jun 1;140(11):2587-2595. doi: 10.1002/ijc.30668. Epub 2017 Mar 11.

PMID:
28233295
15.

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.

Barba M, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, Mentuccia L, Iezzi L, Gamucci T, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M.

BMC Cancer. 2017 Feb 6;17(1):101. doi: 10.1186/s12885-016-3045-z.

16.

Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases.

Manic G, Corradi F, Sistigu A, Siteni S, Vitale I.

Int Rev Cell Mol Biol. 2017;328:105-161. doi: 10.1016/bs.ircmb.2016.08.004. Epub 2016 Oct 18. Review.

PMID:
28069132
17.

Synchronization and Desynchronization of Cells by Interventions on the Spindle Assembly Checkpoint.

Jemaà M, Manic G, Vitale I.

Methods Mol Biol. 2017;1524:77-95.

PMID:
27815897
18.

Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment.

Buglioni S, Vici P, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, Vincenzoni C, Mariani L, Vizza E, Venuti A, Sanguineti G, Gadducci A, Barba M, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M.

Oncoimmunology. 2016 Mar 28;5(6):e1160187. doi: 10.1080/2162402X.2016.1160187. eCollection 2016 Jun.

19.

Trial watch - inhibiting PARP enzymes for anticancer therapy.

Sistigu A, Manic G, Obrist F, Vitale I.

Mol Cell Oncol. 2015 Jun 10;3(2):e1053594. doi: 10.1080/23723556.2015.1053594. eCollection 2016 Mar. Review.

20.

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Manic G, Obrist F, Sistigu A, Vitale I.

Mol Cell Oncol. 2015 Feb 23;2(4):e1012976. doi: 10.1080/23723556.2015.1012976. eCollection 2015 Oct-Dec. Review.

21.

Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins.

Sica V, Manic G, Kroemer G, Vitale I, Galluzzi L.

Methods Mol Biol. 2016;1417:231-45. doi: 10.1007/978-1-4939-3566-6_17.

PMID:
27221495
22.

LTX-315, CAPtivating immunity with necrosis.

Sistigu A, Manic G, Vitale I.

Cell Cycle. 2016 May 2;15(9):1176-7. doi: 10.1080/15384101.2016.1160609. Epub 2016 Mar 17. No abstract available.

23.

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.

Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, Dattilo R, Bartucci M, Vincenzoni C, Mariani L, Vizza E, Sanguineti G, Gadducci A, Vitale I, Barba M, De Maria R, Mottolese M, Maugeri-Saccà M.

PLoS One. 2016 Mar 1;11(3):e0149872. doi: 10.1371/journal.pone.0149872. eCollection 2016.

24.

Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.

Jemaà M, Manic G, Lledo G, Lissa D, Reynes C, Morin N, Chibon F, Sistigu A, Castedo M, Vitale I, Kroemer G, Abrieu A.

Oncotarget. 2016 Jan 5;7(1):885-901. doi: 10.18632/oncotarget.6432.

25.

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.

Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M.

Oncotarget. 2015 Dec 15;6(40):42773-80. doi: 10.18632/oncotarget.6001.

26.

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G.

Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.

27.

Karyotypic Aberrations in Oncogenesis and Cancer Therapy.

Vitale I, Manic G, Senovilla L, Kroemer G, Galluzzi L.

Trends Cancer. 2015 Oct;1(2):124-135. doi: 10.1016/j.trecan.2015.08.001. Epub 2015 Oct 1. Review.

PMID:
28741522
28.

Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.

Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G.

Oncoimmunology. 2015 Jul 25;4(8):e988042. eCollection 2015 Aug.

29.

Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.

Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G.

Ann Oncol. 2015 Dec;26(12):2470-7. doi: 10.1093/annonc/mdv393. Epub 2015 Sep 19.

PMID:
26387143
30.

Role of autophagy in the maintenance and function of cancer stem cells.

Vitale I, Manic G, Dandrea V, De Maria R.

Int J Dev Biol. 2015;59(1-3):95-108. doi: 10.1387/ijdb.150082iv. Review.

31.

The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.

Maugeri-Saccà M, Barba M, Pizzuti L, Vici P, Di Lauro L, Dattilo R, Vitale I, Bartucci M, Mottolese M, De Maria R.

Expert Rev Mol Med. 2015 Jul 2;17:e14. doi: 10.1017/erm.2015.12. Review.

PMID:
26136233
32.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

33.

Trial Watch: Radioimmunotherapy for oncological indications.

Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e954929. eCollection 2014 Oct. Review.

34.

Trial Watch: Proteasomal inhibitors for anticancer therapy.

Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L.

Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun. Review.

35.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
36.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

37.

PARP and other prospective targets for poisoning cancer cell metabolism.

Michels J, Obrist F, Castedo M, Vitale I, Kroemer G.

Biochem Pharmacol. 2014 Nov 1;92(1):164-71. doi: 10.1016/j.bcp.2014.08.026. Epub 2014 Sep 6. Review.

PMID:
25199458
38.

MCL-1 dependency of cisplatin-resistant cancer cells.

Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G.

Biochem Pharmacol. 2014 Nov 1;92(1):55-61. doi: 10.1016/j.bcp.2014.07.029. Epub 2014 Aug 12.

PMID:
25107702
39.

Systems biology of cisplatin resistance: past, present and future.

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G.

Cell Death Dis. 2014 May 29;5:e1257. doi: 10.1038/cddis.2013.428. Review.

40.

Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention.

Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, Boilève A, Obrist F, Bordenave C, Garcia P, Michels J, Jemaà M, Kepp O, Castedo M, Kroemer G.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3020-5. doi: 10.1073/pnas.1318440111. Epub 2014 Feb 10.

41.

Chloroquine and hydroxychloroquine for cancer therapy.

Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L.

Mol Cell Oncol. 2014 Jul 15;1(1):e29911. doi: 10.4161/mco.29911. eCollection 2014. Review.

42.

Trial Watch: Anticancer radioimmunotherapy.

Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Sep 1;2(9):e25595. Epub 2013 Jul 3. Review.

43.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Oct 1;2(10):e25771. Epub 2013 Jul 29. Review.

44.

Predictive biomarkers for cancer therapy with PARP inhibitors.

Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G.

Oncogene. 2014 Jul 24;33(30):3894-907. doi: 10.1038/onc.2013.352. Epub 2013 Sep 16. Review.

PMID:
24037533
45.

Characterization of novel MPS1 inhibitors with preclinical anticancer activity.

Jemaà M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U, Koppitz M, Lienau P, Prechtl S, Schulze V, Siemeister G, Wengner AM, Mumberg D, Ziegelbauer K, Abrieu A, Castedo M, Vitale I, Kroemer G.

Cell Death Differ. 2013 Nov;20(11):1532-45. doi: 10.1038/cdd.2013.105. Epub 2013 Aug 9.

46.

Impact of the Ku complex on HIV-1 expression and latency.

Manic G, Maurin-Marlin A, Laurent F, Vitale I, Thierry S, Delelis O, Dessen P, Vincendeau M, Leib-Mösch C, Hazan U, Mouscadet JF, Bury-Moné S.

PLoS One. 2013 Jul 29;8(7):e69691. doi: 10.1371/journal.pone.0069691. Print 2013.

47.

Cisplatin resistance associated with PARP hyperactivation.

Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G.

Cancer Res. 2013 Apr 1;73(7):2271-80. doi: 10.1158/0008-5472.CAN-12-3000.

48.

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells.

Senovilla L, Vitale I, Martins I, Kepp O, Galluzzi L, Zitvogel L, Castedo M, Kroemer G.

Oncoimmunology. 2013 Jan 1;2(1):e22409.

49.

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G.

Cell Cycle. 2013 Mar 15;12(6):877-83. doi: 10.4161/cc.24034. Epub 2013 Feb 21.

50.

Prognostic value of LIPC in non-small cell lung carcinoma.

Galluzzi L, Goubar A, Olaussen KA, Vitale I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, Validire P, Fouret P, Behrens C, Wistuba II, Soria JC, Kroemer G.

Cell Cycle. 2013 Feb 15;12(4):647-54. doi: 10.4161/cc.23517. Epub 2013 Jan 23.

Supplemental Content

Loading ...
Support Center